This study focuses on testing the safety and how well a new drug called MORAb-202 works for people with a type of lung cancer called metastatic non-small cell lung cancer adenocarcinoma (NSCLC AC). "Metastatic" means the cancer has spread from where it first started to other parts of the body. Participants need to have had previous treatments for their cancer. The study will monitor side effects and see how well the cancer responds to this new treatment. To be part of the study, participants need to have specific medical tests to prove they have this type of cancer. They also need to be in good physical condition, which means they can carry on with normal activities or have some symptoms but can still take care of themselves.

However, people who have other types of lung cancer, like squamous cell carcinoma, or have certain health issues, like fluid buildup that needs to be drained, cannot join. Also, those who have had a lung removed or recent chest radiation might not be eligible. There are other rules about who can join the study too.

• Study looks at safety and response to the treatment.
• Eligibility requires specific cancer type and good physical health.
• Excludes individuals with certain health conditions or recent treatments.